GLP-1 medications and PCOS: what the evidence actually shows

• Treating PCOS itself is off-label; separate on-label use requires meeting the chosen product's labeled indication, such as obesity or type 2 diabetes criteria.
• A recent meta-analysis in women with PCOS found that GLP-1 receptor agonists reduced body weight, BMI, fasting insulin, and HOMA-IR, but nausea, vomiting, and dizziness were more common.
• Pregnancy and contraception instructions differ by product, so follow the instructions for the specific product you are prescribed.

This article is not individualized medical advice; discuss with your clinician whether a GLP-1 medicine fits your situation.

A 2025 meta-analysis of randomized controlled trials examined GLP-1 receptor agonists in adult women with PCOS. It compared the medicines against metformin or placebo. The analysis reported reductions in body mass index, body weight, waist circumference, waist-to-hip ratio, and abdominal girth. For glucose-related measures, it found reductions in fasting insulin, two-hour glucose after an oral glucose tolerance test, and HOMA-IR.

Metabolic benefits

The same meta-analysis showed that GLP-1 receptor agonists reduced BMI, body weight, and insulin resistance in participants with PCOS. These are metabolic outcomes: they describe what the medicine does to weight and blood markers, not reproductive endpoints.

The product labels for the individual medicines describe the receptor actions that produce those metabolic effects. Semaglutide, the active ingredient in Wegovy and Ozempic, is a GLP-1 receptor agonist. Tirzepatide, the active ingredient in Zepbound and Mounjaro, activates both the GIP receptor and the GLP-1 receptor. The label mechanisms do not by themselves demonstrate a treatment effect specific to PCOS.

Hormonal and reproductive effects

In the meta-analysis, all measured hormonal parameters were unchanged. The analysis also reported a reduction in HDL. It did not show improvements in total testosterone, free testosterone, DHEAS, SHBG, or the free androgen index.

The paper did not assess ovulation, fertility, pregnancy outcomes, or any other reproductive endpoint. It stated that “further studies are needed to explore their long-term effects on glucose homeostasis and lipid profiles.” No retained passage establishes GLP-1-driven improvements in fertility independent of weight loss.

Prescribing has increased dramatically. According to data from Truveta, which analyzed records from approximately 1.7 million female patients prescribed semaglutide or tirzepatide and 445,258 patients with PCOS, the rate of semaglutide or tirzepatide prescriptions among patients with PCOS rose from 2.4% in 2021 to 17.6% in 2025, a more than sevenfold increase in four years.

Nearly all of those patients (97.8%) also had obesity and/or type 2 diabetes, conditions for which these medications have FDA-approved indications. That pattern suggests use remains primarily tied to metabolic indications rather than to PCOS as a standalone indication; Truveta noted that further research is needed to determine whether clinical use is expanding to include PCOS-related symptoms and outcomes.

GLP-1 medications are not FDA approved specifically to treat PCOS. The rise in prescribing may reflect both the broader expansion in GLP-1 use and the high prevalence of metabolic conditions among people with PCOS.

The on-label pathway depends on the product and indication. Current Wegovy labeling includes weight reduction for adults with obesity or adults with overweight and at least one weight-related comorbid condition. Current Zepbound labeling includes weight reduction for the same populations and also includes treatment of moderate to severe obstructive sleep apnea in adults with obesity. The obesity indication for Ozempic and Mounjaro does not exist; the current labels for Ozempic and Mounjaro cover glycemic control in adults with type 2 diabetes and, for each product, cardiovascular risk reduction in certain populations.

By contrast, writing a prescription with the treatment goal of “PCOS” is an off-label use regardless of which product is selected. The distinction matters because it defines the evidentiary support for the treatment goal, the monitoring plan, the expected outcomes, and the information a patient receives about alternatives and unknowns.

The warnings differ product by product. Current Zepbound labeling states that Zepbound delays gastric emptying and may reduce the effectiveness of oral hormonal contraceptives. The label advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting Zepbound and for four weeks after each dose escalation.

Wegovy labeling does not contain the same oral-contraceptive language. For Wegovy used for cardiovascular risk reduction or weight reduction, the label instructs patients to discontinue when pregnancy is recognized. For Wegovy used for MASH, the label uses a benefit-risk instruction: use during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Both products have a boxed warning for thyroid C-cell tumors seen in rodents. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.

If pregnancy is a possibility, discuss a plan with the clinician before starting or escalating treatment. For weight reduction or cardiovascular risk reduction, and for MASH when the potential risk outweighs the potential benefit, the Wegovy label recommends discontinuing at least two months before a planned pregnancy because of the long half-life of semaglutide. Do not apply that washout interval to a product that does not carry the same language.

• Treatment goal beyond PCOS: Ask whether the prescription targets weight, glycemic control, cardiovascular risk reduction, or obstructive sleep apnea, and whether that use matches the product's approved indication.
• Measurable endpoints: Agree on which metrics (body weight, fasting insulin, HbA1c, side-effect burden, or nutrition markers) will be tracked and how soon they will be reviewed.
• Reproductive plans: If pregnancy is possible or planned, discuss contraception choice, the need for a non-oral or barrier method with Zepbound, the timing of stopping Wegovy before pregnancy, and the product's pregnancy-warning language.
• Side-effect monitoring: Because the meta-analysis showed increased nausea, vomiting, and dizziness with GLP-1 receptor agonists, decide on a plan for managing gastrointestinal symptoms and what would prompt a dose delay or discontinuation.
• Long-term unknowns: Confirm you understand that the evidence for reproductive, hormonal, and fertility endpoints beyond metabolic improvement is incomplete.

Are GLP-1 medications approved to treat PCOS?

No. No GLP-1 receptor agonist holds an FDA indication to treat PCOS. A person with PCOS can still receive a GLP-1 medicine when the prescription matches the product's approved indication, for example, Wegovy or Zepbound for obesity, provided the label criteria are met.

Does the evidence show that GLP-1 medications improve fertility?

The strongest available evidence, drawn from a 2025 meta-analysis of women with PCOS, measured metabolic parameters and did not assess fertility endpoints. The paper reported unchanged hormone levels (except for HDL). It did not establish improvements in ovulation, fertility, or pregnancy outcomes independent of weight loss.

What does the Zepbound label say about birth control pills?

The current Zepbound label warns that delayed gastric emptying may reduce the effectiveness of oral hormonal contraceptives. It advises patients using oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting Zepbound and for four weeks after each dose escalation.

If I am planning a pregnancy, how long before should I stop Wegovy?

For patients using Wegovy for cardiovascular risk reduction or weight reduction, the label recommends discontinuing Wegovy at least two months before a planned pregnancy because of the long half-life of semaglutide. This timing is specific to Wegovy and should not be applied to other GLP-1 products without a prescriber's direction.

What side effects were reported in the PCOS evidence?

The meta-analysis found that GLP-1 receptor agonists increased nausea, vomiting, and dizziness compared with metformin or placebo. Individual product labels also list common side effects such as diarrhea, constipation, abdominal pain, and fatigue.

This article reflects the retained source passages as of the revision date. It does not incorporate newer post-market data, clinical-trial results published after the source cutoff, or individualized medical guidance. Decisions about GLP-1 therapy should be made with a clinician who knows the full clinical picture.